Allena Pharmaceuticals Shares Fall After Filing For Bankruptcy
In its SEC filing, Allena Pharmaceuticals Inc (NASDAQ:ALNA) filed for chapter 11 bankruptcy protection and terminated the employment of substantially…
Amazon’s $3.9B Purchase Of 1Life’s One Medical Faces Delay Due To FTC Investigation
The Federal Trade Commission (FTC) is investigating the $3.9 billion transaction between Amazon.com Inc. (NASDAQ: AMZN) and 1Life Healthcare Inc. (NASDAQ: ONEM).
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved expanded use of Vertex’s (NASDAQ:VRTX) lead asset ORKAMBI (lumacaftor/ivacaftor) to…
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
The White House is seeking $44.5 billion in emergency funding from Congress for Covid-19 and monkeypox and back…
Vertex Pharma’s Flagship Cystic Fibrosis Drug Scores FDA Approval For Infants
The FDA has approved Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) Orkambi (lumacaftor/ivacaftor) for expanded use to include children with cystic fibrosis (CF) ages…
Veterans File Lawsuit To Block 3M Healthcare Spinoff: Report
Two U.S. military veterans have reportedly sued 3M Co (NYSE:MMM) to block the planned spinoff of its healthcare business, calling it…
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback
Raymond James initiated coverage on AnaptysBio Inc (NASDAQ:ANAB) with an Outperform rating and a $35 price target. The analyst has a positive…
Johnson & Johnson To Settle New Hampshire Opioid Lawsuit With Payment Of $40.5M: Report
Reuters reported that Johnson & Johnson (NYSE:JNJ) would pay $40.5 million to settle 2018 New Hampshire’s claims about the U.S. opioid epidemic,…
PolyPid’s Lead Program Flunks Abdominal Surgery Study, Shares Tank
PolyPid Ltd (NASDAQ: PYPD) shares lost almost 80% after announcing topline results from the SHIELD I Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal surgery.
Immuneering Shares Climb After Pursuing FDA Nod For RAS Mutant Tumor Study
Immuneering (NASDAQ: IMRX) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors.